Intellectual Product
2025 FDA staff cuts and their impact on new drug review timelines
FDA layoffs 2025; drug review timelines; user fee programs; HHS staff cuts; RFK Jr. layoffs; PDUFA; regulatory timelines; drug approvals; FDA workforce reductions
2025 FDA staff cuts and their impact on new drug review timelines
FDA layoffs 2025; drug review timelines; user fee programs; HHS staff cuts; RFK Jr. layoffs; PDUFA; regulatory timelines; drug approvals; FDA workforce reductions
2025 FDA staff cuts and their impact on new drug review timelines
FDA layoffs 2025; drug review timelines; user fee programs; HHS staff cuts; RFK Jr. layoffs; PDUFA; regulatory timelines; drug approvals; FDA workforce reductions
2025 FDA staff cuts and their impact on new drug review timelines
FDA layoffs 2025; drug review timelines; user fee programs; HHS staff cuts; RFK Jr. layoffs; PDUFA; regulatory timelines; drug approvals; FDA workforce reductions
OpenAI launches ChatGPT Health as a dedicated, privacy-focused health assistant
OpenAI; ChatGPT Health; healthcare AI; medical records integration; Apple Health; wellness apps; health data privacy; HealthBench; b.well partnership; AI in healthcare
Alumis’ TYK2 Inhibitor Envudeucitinib Succeeds in Phase 3 Psoriasis Trials, Plans FDA Filing
Alumis; envudeucitinib; TYK2 inhibitor; psoriasis; Phase 3 trials; FDA approval; PASI 75
Innovative Solutions for Difficult-to-Express Proteins: Cell-Free Systems and AI-Driven Advances
cell-free protein expression; difficult-to-express proteins; AI protein design; in vitro expression; alternative proteins
Breakthrough Real-World Evidence Powering Blood Cancer Research in 2025
RWE; blood cancer; real-world evidence; ASH 2025; SOHO 2025; hematologic care
Endpoints News Topics at 2026 JPM Healthcare Conference: CEOs, Investors, China, and Beyond
JPM Healthcare Conference; Endpoints News; CEOs; investors; AI healthcare; biopharma; private equity
Quantori and Expert Systems Partner to Accelerate Drug Discovery with Foundational Predictive AI Models
Quantori; Expert Systems; drug discovery; AI models; Q-Scientist; pharmaceutical R&D